Product Description
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Chile | China | Croatia | Cyprus | Egypt | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Lebanon | Malaysia | Malta | Netherlands | New Zealand | Norway | Pakistan | Poland | Russia | Serbia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Baxter Healthcare
Company Location: DEERFIELD IL 60015
Company CEO: José E. Almeida
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Muscle Weakness
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SeND Home | P2 |
Recruiting |
Muscle Weakness |
2025-06-30 |
2024-10-18 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/27/2025 |
News Article |
Thermostatic Mixing Valve Market to Reach USD 1,749.6 million By 2032, Growing At An 5 % CAGR - Credence Research |
|
04/10/2025 |
News Article |
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting |
|
03/25/2025 |
News Article |
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data |
|
02/24/2025 |
News Article |
3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics |